Milveterol

Drug Profile

Milveterol

Alternative Names: 159797; GSK 159797; TD 3327

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline; Theravance
  • Developer GlaxoSmithKline
  • Class Amines; Antiasthmatics; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 10 Apr 2007 Results from a phase IIb clinical trial in patients with asthma added to the Obstructive Airways Disease therapeutic trials sections ,
  • 19 Aug 2005 Data from a media release have been added to the Obstructive Airways Disease therapeutic trials section
  • 18 Jan 2005 Data presented at the JP Morgan H&Q 23rd Healthcare Conference (JP Morgan-2005) have been added to the adverse events and Obstructive Airways Disease therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top